Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06658353 | Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors | recruiting | Phase 3 | 54 | Jiangsu vcare pharmaceutical technology co., LTDINDUSTRY | 1 | Jul 27, 2026 | clinicaltrials |
| NCT04939610 | A Study of 177Lu-FAP-2286 in Advanced Solid Tumors(LuMIERE) | recruiting | Phase 1 / Phase 2 | 222 | Novartis PharmaceuticalsINDUSTRY | 6 | Jul 24, 2026 |
| NCT06445517 | Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma | recruiting | Phase 1 | 60 | InSilico Medicine Hong Kong LimitedINDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07002203 | Personalized Neoantigen Peptide Vaccines for Solid Tumors | recruiting | Phase 1 / Phase 2 | 10 | Seqker Biosciences, Inc.INDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07098299 | Metformin Combined With Chemotherapy and/or Immunotherapy in Solid Malignancies | recruiting | Phase 1 | 60 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07362888 | First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 180 | Adcendo ApSINDUSTRY | 2 | Jul 24, 2026 | clinicaltrials |
| NCT07460375 | A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 191 | LigaChem Biosciences, Inc.INDUSTRY | 3 | Jul 24, 2026 | clinicaltrials |
| NCT07724756 | Phase II Study of QLC2519 in Pediatric Solid Tumor Participants | recruiting | Phase 2 | 18 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT03917043 | APG-2449 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 165 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT03934372 | Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors | recruiting | Phase 1 / Phase 2 | 70 | Incyte Biosciences International SàrlINDUSTRY | 7 | Jul 23, 2026 | clinicaltrials |
| NCT05719558 | A Study of ASP1002 in Adults for Treatment of Solid Tumors | recruiting | Phase 1 | 798 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT05836324 | A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 570 | Incyte CorporationINDUSTRY | 9 | Jul 23, 2026 | clinicaltrials |
| NCT06234098 | Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors | recruiting | Phase 1 / Phase 2 | 100 | Alyssum TherapeuticsINDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06475300 | A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors | recruiting | Phase 2 | 570 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06545942 | Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 220 | MOMA TherapeuticsINDUSTRY | 3 | Jul 23, 2026 | clinicaltrials |
| NCT06719362 | A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies | recruiting | Phase 1 | 110 | Providence Health & ServicesOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06942104 | Imaging of Solid Tumors Using 18F-TRX | recruiting | Phase 1 | 56 | Rahul AggarwalOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06974110 | Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 132 | MOMA TherapeuticsINDUSTRY | 2 | Jul 23, 2026 | clinicaltrials |
| NCT07172919 | A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation | recruiting | Phase 2 | 14 | AmgenINDUSTRY | 9 | Jul 23, 2026 | clinicaltrials |
| NCT07374848 | Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors | recruiting | Phase 1 | 180 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 2 | Jul 23, 2026 | clinicaltrials |
| NCT07589205 | Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors | recruiting | Phase 1 | 493 | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT05098210 | Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer | recruiting | Phase 1 | 28 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT06179160 | A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | recruiting | Phase 1 | 710 | Incyte CorporationINDUSTRY | 8 | Jul 22, 2026 | clinicaltrials |
| NCT06721689 | PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors(PEEL-224) | recruiting | Phase 1 / Phase 2 | 59 | Theodore LaetschOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07524322 | Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors | recruiting | Phase 1 | 63 | Regor Pharmaceuticals Inc.INDUSTRY | 1 | Jul 22, 2026 | clinicaltrials |
| NCT02421380 | Characterization of Hyperpolarized Pyruvate MRI Reproducibility | recruiting | N/A | 109 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT05098132 | Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers(SYNERGY-101) | recruiting | Phase 1 / Phase 2 | 364 | SynthekineINDUSTRY | 4 | Jul 21, 2026 | clinicaltrials |
| NCT06687070 | APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST | recruiting | Phase 1 | 90 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07368127 | A Study of TPD3310 in Patients With Advanced Malignant Tumors | recruiting | Phase 1 | 112 | TAIBIDI PHARMACEUTICAL TECHNOLOGY(SHIJIAZHUANG) CO.,LTD.INDUSTRY | 1 | Jul 20, 2026 | clinicaltrials |
| NCT00992303 | Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy and Healthy Participants | recruiting | — | 10,000 | University of Texas Southwestern Medical CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07712029 | Phase II Study of Becotatug Vedotin Plus Pucotenlimab for Advanced Refractory Solid Tumors With EGFR-Positive | recruiting | Phase 2 | 32 | Tianjin Medical University Second HospitalOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT05092373 | Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax | recruiting | Phase 1 | 43 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05673928 | A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB) | recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05705492 | Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer | recruiting | Phase 2 | 66 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06941324 | Solution-Focused Brief Therapy for Support of Psychological Distress in Adolescent and Young Adult Cancer Survivors | recruiting | N/A | 60 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07189195 | TR-002 for the Treatment of Advanced Unresectable Metastatic Solid Tumors Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma | recruiting | Phase 1 | 52 | University of California, DavisOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03819296 | Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer | recruiting | Phase 1 | 800 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT05053971 | Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors | recruiting | Phase 1 / Phase 2 | 49 | National Cancer Institute (NCI)NIH | 1 | Jul 15, 2026 | clinicaltrials |
| NCT06265688 | First In Human Study of CX-2051 in Advanced Solid Tumors | recruiting | Phase 1 | 160 | CytomX TherapeuticsINDUSTRY | 1 | Jul 15, 2026 | clinicaltrials |
| NCT06587295 | Intramuscular ACM-CpG Monotherapy in Patients With Advanced/Metastatic Solid Tumors With Prior Response to Immunotherapy Alone or in Combination With Chemotherapy | recruiting | Phase 1 | 40 | National Cancer Centre, SingaporeOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT06657144 | A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 154 | Coherus Oncology, Inc.INDUSTRY | 2 | Jul 15, 2026 | clinicaltrials |
| NCT04494945 | Identifying and Caring for Individuals With Inherited Cancer Syndrome | recruiting | N/A | 27,500 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05533697 | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 361 | ModernaTX, Inc.INDUSTRY | 7 | Jul 14, 2026 | clinicaltrials |
| NCT07556653 | Allogeneic WTX-212C in Advanced Solid Tumors(WTX-212C-IIT) | recruiting | Early Phase 1 | 24 | Zhejiang Provincial People's HospitalOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07702162 | A Clinical Study of PA5 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 49 | Chongqing Peg-Bio Biopharm Co., Ltd.INDUSTRY | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05250284 | The Intersection of Oncology Care and Worker Well-Being | recruiting | — | 400 | University of Colorado, DenverOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07137416 | Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer | recruiting | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07697937 | YH02 Injection for Intra-tumor Injection Therapy in Advanced Solid Tumors With Unresponsive or Failure-Treated Cases(YH02) | recruiting | Phase 2 | 50 | Tianjin First Central HospitalOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06997029 | A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors | recruiting | Phase 1 | 234 | Bristol-Myers SquibbINDUSTRY | 3 | Jul 10, 2026 | clinicaltrials |
| NCT07617493 | Evaluation of ICP-B208 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 539 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 27, 2026source: clinicaltrials